<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541736</url>
  </required_header>
  <id_info>
    <org_study_id>FHM-GTN-2007-08</org_study_id>
    <nct_id>NCT00541736</nct_id>
  </id_info>
  <brief_title>Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine</brief_title>
  <official_title>Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EUROHEAD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to explore the importance of migraine genes on the
      headache/migraine responses after GTN in FHM-patients and healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks
      in approximately 80% of migraine sufferers. After systemic administration GTN is transformed
      to nitric oxide (NO). Treatment of spontaneous migraine attacks with an inhibitor of NO is
      effective in 60% of patients. These data show that NO is involved in both initiation and
      maintenance of migraine attack.

      The importance of migraine genes is disputed. Evidence from FHM patients with known mutations
      indicates that migraine pathways in FHM may be different from normal migraine. The aim of the
      present study is to examine whether this difference also exists in FHM patients without known
      mutations. The project will improve our understanding of the neurobiology of migraine and
      stimulate development of new treatment targets.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Migraine and associated symptoms</measure>
    <time_frame>0-14 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Migraine aura</measure>
    <time_frame>0 - 14 h</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Familial Hemiplegic Migraine</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GTN-infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GTN-infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerine</intervention_name>
    <description>Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of familial hemiplegic migraine (IHS-classification criteria)

        Exclusion Criteria:

        Patients and controls:

          -  A history of cerebrovascular disease and other CNS- disease

          -  A history of serious somatic and mental disease

          -  A history suggesting ischaemic heart disease

          -  A history of hypo- or hypertension

          -  Daily intake of medication apart from oral contraceptives

          -  Abuse of alcohol or medicine (opioid analgesics).

          -  Pregnant or breastfeeding women.

        On the study day:

          -  No intake of a simple analgesic in the previous 48 hours

          -  No headache in the previous 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob MÃ¸ller Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital</name>
      <address>
        <city>Glostrup, Copenhagen</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <last_update_submitted>May 28, 2008</last_update_submitted>
  <last_update_submitted_qc>May 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2008</last_update_posted>
  <keyword>Familial Hemiplegic Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

